Cellbxhealth PLC: TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB0034330679
Issuer Name
CelLBxHealth plc
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Conifer Management, L.L.C.
City of registered office (if applicable)
New York
Country of registered office (if applicable)
United States
4. Details of the shareholder
|
Name |
City of registered office |
Country of registered office |
|
Pershing LLC |
Jersey City |
USA |
5. Date on which the threshold was crossed or reached
18-Dec-2025
6. Date on which Issuer notified
22-Dec-2025
7. Total positions of person(s) subject to the notification obligation
|
. |
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
Resulting situation on the date on which threshold was crossed or reached |
29.900000 |
0.000000 |
29.900000 |
340681395 |
|
Position of previous notification (if applicable) |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
|
GB0034330679 |
340681395 |
29.900000 |
||
|
Sub Total 8.A |
340681395 |
29.900000% |
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
Sub Total 8.B1 |
||||
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
Sub Total 8.B2 |
|||||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
|
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
Gregory Alexander |
Conifer Management, LLC |
29.900000 |
29.900000% |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
Shares are held in private funds managed by Conifer Management, LLC
12. Date of Completion
22-Dec-2025
13. Place Of Completion
New York, NY
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Cellbxhealth PLC
View the original press release on ACCESS Newswire
SOLANA BEACH, Calif.--(BUSINESS WIRE)--Macnica Americas today announced the appointment of Nestor Amaya as Vice President…
Every year, millions of Americans who miss their tax filing deadlines assume the IRS is…
Genius Sports has deployed its cutting-edge data and AI platform GeniusIQ in every Liga MX…
Starting June 4, My Best Buy Plus™ and My Best Buy Total™ members will automatically…
New platform combines 17 years of proprietary compliance data with direct access to credentialed experts,…
Translational Data Inform a Scalable, Noninvasive Test Designed to Identify Treatment-Eligible Patients and Enable Longitudinal…